Shares of Anika Therapeutics Inc. skidded lower after the Bedford company said that the Food and Drug Administration had upheld its decision against approving Anika’s osteoarthritis treatment, Monovisc. The company said it will schedule a meeting with the FDA and then decide on its next steps. Monovisc is designed to treat pain in patients who suffer from osteoarthritis of the knee. It has been on the market in Europe since 2008 and was approved in Canada in 2009.
FDA upholds rejection of Anika treatment
December 06, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢